Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

In one of the flexible-dose studies, the numeric improvement in SDS total score of the levomilnacipran ER group did not reach statistical significance relative to the placebo group ( Gommoll et al. , 2014 ); this was also true for the primary efficacy measure (MADRS) in that study.

also in 111,027 other papers